FGFR4 and hepatocellular carcinoma: FGF401 (Novartis) is a tyrosine kinase inhibitor with high selectivity against FGFR4 compared to FGFR1-3 and is under investigation in a phase I/II study in patients with hepatocellular carcinoma with FGFR4 and Klothoβ expression (ClinicalTrials.gov Identifier: NCT02325739).